

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/16, 7/22, 9/16, 31/155	A1	(11) International Publication Number: WO 96/11666
		(43) International Publication Date: 25 April 1996 (25.04.96)

(21) International Application Number: PCT/US95/13337

(22) International Filing Date: 11 October 1995 (11.10.95)

(30) Priority Data:
322,926 13 October 1994 (13.10.94) US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

322,926 (CON)

13 October 1994 (13.10.94)

(71) Applicant (for all designated States except US): GILLETTE
CANADA INC. [CA/CA]; 16700 Trans Canada, Kirkland,
Quebec H9H 4Y8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MASTERMAN, Thomas,
Craig [US/US]; 35 Myrtle Street #3, Boston, MA 02114
(US). SPENCER, Jean, L. [US/US]; 19 Middle Street #4,
Boston, MA 02127 (US).(74) Agents: HANDELMAN, Joseph, H.; Ladas & Parry, 26 West
61st Street, New York, NY 10023 (US) et al.(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA,
CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP,
KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE,
MW, SD, SZ, UG).

Published

With international search report.

(54) Title: PARTICLES INCLUDING DEGRADABLE MATERIAL AND ANTI-MICROBIAL AGENT

(57) Abstract

A method for inhibiting bacteria in the mouth of a patient which includes placing a particle containing a degradable material and an anti-microbial agent in the mouth of the patient. The exterior of the particle is water-stable. The particles may be coated on dental floss or the bristles of a toothbrush, or incorporated into an oral rinse. Once placed in the mouth, the degradable material degrades to cause release of the anti-microbial agent, resulting in the inhibition of bacteria in the mouth.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

PARTICLES INCLUDING DEGRADABLE
MATERIAL AND ANTI-MICROBIAL AGENT

The invention relates to systems for delivering anti-microbial agents to the mouth.

5 Many humans suffer from tooth decay and periodontal disease caused by bacteria in the mouth. As a result, decreasing the number of these bacteria is a problem which has been targeted by members of the dental and health
10 care fields. The most common way of minimizing the number of bacteria is to brush and floss the teeth regularly, and to visit a dental hygienist to have the teeth and gums cleaned thoroughly. Another approach to control bacteria in the
15 mouth is to rinse with a solution containing an effective anti-microbial agent, such as chlorhexidene digluconate.

One of the major side effects of rinsing with a chlorhexidene-based solution is a
20 yellow-brown stain which may develop on the teeth, tongue, and fillings. Although this stain can usually be professionally removed, it is not cosmetically pleasing. In addition to the staining, taste disturbances, such as the
25 perception of sweets and salt, may develop due to the presence of chlorhexidene. In certain patients, scaling and soreness of the oral

- 2 -

mucosa may occur. These side effects have been attributed to the high concentration of chlorhexidene (or salt thereof) used in the rinse; it is, therefore, desirable to reduce or control the dosage of chlorhexidene so that anti-microbial effects can be achieved without the onset of undesirable side effects.

In general, the invention features a method for inhibiting bacteria in the mouth of a patient. The method includes placing a particle containing a degradable material and an anti-microbial agent into the mouth of a patient. The saliva in the mouth causes the degradable material in the particle to degrade, resulting in the release of the anti-microbial agent in a controlled manner over time. The exterior of the particle is water-stable allowing the particles to be incorporated into, for example, aqueous rinses or pastes without the water in the rinse or paste causing the degradable material to degrade prematurely, prior to use.

In one embodiment, the particle is provided with a coating composed of a water-stable material that does not degrade when exposed to one or more enzymes in the mouth. These materials include hydrophobic materials like poly(methyl methacrylate), polystyrene, beeswax, carnauba wax, petroleum wax, or similar materials. The coating is disrupted by mechanical stresses (e.g., brushing, flossing, and chewing); this disruption exposes the underlying degradable material to saliva. As a result, the degradable material degrades, causing the anti-microbial agent to be released.

In another embodiment, the particle is provided with a coating of a water-stable material that degrades when exposed to one or

- 3 -

more enzymes in the mouth. Examples of such materials include polyhydroxyalkanoic acid, glycolipids, glycerides, and phospholipids. As the water-stable material degrades by the action of enzymes in the mouth, the underlying degradable material is exposed to saliva and also degrades, resulting in the release of the anti-microbial agent. The water-stable material may also be disrupted by mechanical stresses.

In another embodiment, the particle includes a water-stable material, dispersed throughout the particle, that degrades when exposed to enzymes in the mouth. In this embodiment, the water-stable material (1) functions as the degradable material, and (2) functions to provide the particle with a water-stable exterior. Optionally, the particle may include one or more other degradable materials underneath the water-stable exterior, and also may include one or more other water-stable materials that help provide the water-stable exterior. A preferred material that can be used for this embodiment is glycerol distearate.

Preferred anti-microbial agents include phenolic compounds (monomeric or polymeric, synthetic or natural); nature-derived anti-microbials such as sanguinarine; cetylpyridinium salts; benzalkonium salts; benzethonium salts; domiphen salts; bisbiguanides, such as chlorhexidene; bisbiguanide salts; phosphonium salts; ammonium salts; peroxides and other oxidants; zinc salts; and antibiotics such as penicillin, vancomycin, kanamycin, erythromycin, niddamycin, spiramycin, tetracycline, minocycline, and metronidazole. Particularly preferred anti-microbial agents include chlorhexidene or an acceptable salt of

- 4 -

chlorhexidene.

Preferred degradable materials include polyglycolic acid, polylactic acid, and copolymers of glycolic acid and lactic acid, and
5 esters of glycerol.

In some preferred embodiments, the degradable material encapsulates the anti-microbial agent. In other preferred
10 embodiments, the particle is a microsphere, and the diameter of the microsphere is preferably between 0.05 μm and 100 μm , more preferably between 0.1 μm and 30 μm .

In another aspect, the invention features a toothbrush including a handle and,
15 extending from a portion of the handle, bristles coated with the particles of the invention, or hollow bristles that are partially or totally filled with the particles. In another aspect, the invention features dental floss including an
20 elongated, flexible cord (preferably made of nylon or other durable polymer) coated with the particles of the invention. In still another aspect, the invention features a toothpaste or an oral rinse containing the particles of the
25 invention. The toothpaste generally includes other conventional components such as an abrasive (e.g., silica or alumina, having a particle size of between 5 μm and 50 μm), a thickener (e.g., colloidal silica having a
30 particle size of between 0.1 μm and 1 μm), and a flavor.

"Encapsulate", as used herein, means that the anti-microbial agent is dispersed throughout or surrounded by the degradable
35 material.

"Degradable material", as used herein, means a material which degrades within three

- 5 -

months when placed in the mouth of a typical patient. The materials degrade as a result of exposure to one or more enzymes that commonly are found in the mouth. These enzymes include
5 lipases, proteases, and glucosidases. Specific enzymes include parotid amylase, hyaluronidase, beta-glucuronidase, chondroitin sulfatase, amino acid decarboxylases, catalase, peroxidase (such as lacto peroxidase), collagenase, and lysozyme.

10 "Water-stable exterior", as used herein, means that the exterior surface of the particle is composed of a material that does not chemically degrade or swell when exposed to water. As a result of the water-stable
15 exterior, substantially no (i.e., less than 5% by weight) anti-microbial agent leaches from the particle when the particle is placed in distilled water (at a concentration of 10% of the dispersion by weight) at room temperature
20 for a month.

"Microsphere", as used herein, means that the particle is substantially spherical in shape.

The particles of the invention can be
25 used to deliver an anti-microbial agent at a predetermined rate for a defined time period. The degradable material essentially allows for continuous inhibition of bacteria in the mouth during the selected time period without
30 necessitating a large initial dosage of the anti-microbial agent. The dosage optionally may be provided in a site-specific manner. The water-stable exterior allows the particles to be stored for a substantial period of time, for
35 example in a mouthwash or a toothpaste.

When chlorhexiden is selected as the anti-microbial agent, the controlled delivery

- 6 -

process of the invention results in a reduction of undesirable side effects, such as staining of the teeth and tongue. Significantly, when the particles are composed primarily of a degradable material and an anti-microbial agent, substantially nothing remains of the particles in the mouth or body once the degradable material degrades and all of the anti-microbial agent is released.

10 The preferred particles include a degradable material, an anti-microbial agent, and a thin (e.g., less than 10 μ m) non-porous coating that makes the exterior surface of the particle water-stable.

15 Preferred degradable materials include polymers such as polycaprolactone, polydecalactone, poly(sebacic anhydride), sebacic acid-co-1,3-bis(carboxyphenoxypropane), sebacic acid-co-1,6-bis(carboxyphenoxyhexane),
20 dedecanoic-co-1,3-bis(carboxyphenoxypropane), dedecanoic-co-1,6-bis(carboxyphenoxyhexane), albumin and derivatives, gelatin and derivatives, starch and derivatives, gum arabic, cellulose and derivatives, polysorbate and
25 derivatives, agarose, lectins, galactose, functionalized nylons (e.g. benzylated), proteins (synthetic and natural), polyorthoesters, polyorthoformate, polyureas, polyurethanes, poly(amide-enamine)s,
30 polyvinylalcohol, polyenolketone (PEK), polyHema, functionalized polyHema, ethylene-vinylacetate copolymers, functionalized polymers and copolymers of lactic and glycolic acid, lactic acid homopolymer, glycolic acid
35 copolymer, copolymers of lactic acid and glycolic acid, polyhydroxybutyrate, poly(ester amides), functionalized silicones,

- 7 -

poly(anhydrides), poly(malic acid), and polyhydroxyalkanoic acid from synthetic or natural sources (bacterial, fungi and the like). Other preferred degradable materials include

5 monomeric species and mixed monomeric/polymeric species such as liposomes, glycolipids, fatty acids, glycerides, carnauba wax, and phospholipids.

The preferred degradable materials can

10 be included in organic/inorganic composites. The composites can include any of the polymers listed above mixed or covalently bound with minerals such as silica, alumina, kaolin, morierite, cordierite, zirconia minerals and the

15 like; any of the monomeric and monomer/polymer species listed above mixed or covalently bound with minerals such as silica, alumina, kaolin, morierite, cordierite, zirconia minerals and the like; proteins bound to silica, titania, and the

20 like; silicon-containing polymers; and polyhydroxyalkanoic acid:salt complexes. The inorganic component(s) of the composite can, for instance, assist in controlling the dosage of anti-microbial agent released in a given period

25 of time, or act as an abrasive if used, e.g., in a toothpaste.

The more preferred degradable materials are polymers such as polyglycolic acid, polylactic acid, and copolymers of

30 glycolic acid and lactic acid, and esters of glycerol. These polymers are well-known and commercially available. For example, polyglycolic acid is available from the American Cyanamid Company (Daxon®) and Polysciences,

35 Inc.; polylactic acid is available from Polysciences, Inc.; and copolymers of glycolic acid and lactic acid are available from American

- 8 -

Cyanamid Company (Vicryl), Ethicon, Inc.
(Polyglactin 910) and Polysciences.

Alternatively, the polymers can be synthesized according to known procedures. For example,
5 polyglycolic acid can be prepared employing the ring opening polymerization of the dimeric ester of glycolic acid; polylactic acid can be prepared employing the ring opening polymerization of the dimeric ester of lactic acid; and
10 copolymers of glycolic acid and lactic acid can be prepared employing the ring opening polymerization of the corresponding dimeric esters.

Other preferred degradable polymeric
15 materials are commercially available and/or may be prepared by known procedures.

A particularly preferred antimicrobial agent is chlorhexidene, an antibacterial compound which contains two biguanide
20 moieties, each attached in the para position to a separate chlorophenyl group, and joined by a hexane linkage (see, for example, Rose et al., J. Chem Soc., p. 4422 (1956) and U.S. Pat. No. 2,684,924). Pharmaceutically acceptable salts
25 of chlorhexidene, such as chlorhexidene gluconate, chlorhexidene diacetate, chlorhexidene dihydrochloride, chlorhexidene dihydrofluoride, and chlorhexidene dihydrobromide may also be used in the present
30 invention. Chlorhexidene and its associated salts are commercially available; the gluconate salt may be purchased, for example, as a 20.5 percent w/w aqueous solution from Pliva Pharmaceutical of Zagreb, Yugoslavia, and from
35 ICI Ltd. of England. Chlorhexidene gluconate as a freeze-dried solid is available from Pliva Pharmaceutical.

- 9 -

Other preferred anti-microbial agents were described above and generally, like chlorhexidene digluconate, are commercially available.

5 The particles preferably include between 1% and 75%, and more preferably between 1% and 25%, of the anti-microbial agent by weight. Too much anti-microbial agent may adversely affect the mechanical strength of the
10 particle, while too little anti-microbial agent may result in an insufficient dosage of the anti-microbial agent being delivered to the mouth.

 The thin non-porous (more preferably
15 hydrophobic) coating prevents the anti-microbial agent from leaching from the particle when the particle is stored or incorporated into aqueous systems. Preferred coating materials include poly(methyl methacrylate), polystyrene, beeswax,
20 carnauba wax, petroleum wax, polyhydroxyalkanoic acid, glycolipids, glycerides, phospholipids, and glycerol distearate. The coating materials may be materials (like polystyrene, waxes, or
25 poly(methyl methacrylate) that do not degrade when exposed to enzymes in the mouth, or may be materials (like glycerol distearate, polyhydroxyalkanoic acid, and other glycerides) that degrade when exposed to enzymes in the
30 mouth. All of these materials are commercially available. Preferably the coating constitutes no more than about 10% of the particle diameter.

 The anti-microbial agent may be dispersed throughout the particle along with the
35 degradable material, enclosed within a skin composed of the degradable material, or attached to a skin composed of the degradable material.

- 10 -

In the latter embodiment, the degradable material and the anti-microbial agent may have opposite ionic charges and the anti-microbial agent may be adsorbed onto the skin by ionic bonding.

The preferred particles are microspheres that have an average diameter between 0.05 μm and 100 μm , more preferably between 0.1 μm and 30 μm . If the particles are too large they will too easily wash away from oral surfaces and thus will be less likely to settle subgingivally.

The preferred particles can be made by numerous conventional, well-known methods. These include solvent evaporation methods, with or without a surface active agent as necessary, coacervation in all its various forms, pan coating, air-suspension coating, press coating, spray-drying, rotational suspension-separation techniques, melt coating methods, interfacial polymerization, melt-granulation processes and any and all related methods that yield the desired particles as described. Such methods may or may not use organic solvents. Such methods may encapsulate from solution, from the melt or in powdered (solid state) form. Once formed, the particles may be chemically modified (e.g., charged or made magnetic). The particles are then coated with a water stable material. See, for example, the particle-making and particle-coating procedures described generally in Parrott, Pharmaceutical Technology, pp. 86-91 (Burgess Pub. Co. 1970); Deasy, Microencapsulation and Related Drug Procedures, pp. 1-60 (Marcel Dekker, Inc. 1984); Muller et al., J. Contr lled Release, 20 (1992):237-246; P karek et al., Nature, v. 367 (1994):258-60;

- 11 -

Muller et al., Pharm. Pharmacol. Lett. v. 3 (1993):67-70; and Juliano (ed.), Drug Delivery Systems (Oxford University Press 1980).

The preferred particles can be placed
5 in the mouth of a patient, e.g., by a dental instrument, or can be delivered to the mouth during routine dental hygiene, e.g., using a toothbrush, dental floss, oral rinse or toothpaste. Once the particles are in the oral
10 cavity, they will settle out around the gumline, settle subgingivally, adhere to soft tissue and become immobilized in these areas. The coating can be partially removed during administration of the particles to the mouth, or subsequently
15 during chewing or brushing. If the coating is a material that degrades when contacted with enzymes in the mouth, the coating will additionally (or solely) be removed by degradation after exposure to the enzymes.

20 Once the particle has settled, various release mechanisms are possible. The operative release mechanism(s) will depend upon the formulation of the particle. Thus, as the degradable material erodes, anti-microbial agent
25 is released. This site-specific release can continue (12 hr to several weeks to several months) until the entire particle is degraded or washed from the mouth or swallowed. If the latter occurs, final degradation will occur in
30 the stomach and/or gastrointestinal tract. Thus, no long term build-up of particles systemically should occur.

The following are examples of the
procedures used to make and administer particles
35 of the present invention.

- 12 -

Example 1: Degradable Particles

Degradable particles consisting of poly(DL-lactide)-co-glycolide, 80:20, were prepared according to the following procedure:

- 5 1. 25 mg poly(DL-lactide)-co-glycolide were dissolved in 2 ml methylene chloride.
2. A 1 wt % solution of polyvinylalcohol (87-89% hydrolyzed) was prepared.
- 10 3. The methylene chloride solution was added (all at once) to 30 ml of the 1 % polyvinylalcohol solution.
4. The resulting emulsion was vortexed for 1 minute and then sonicated for 1 minute, providing a turbid emulsion.
- 15 5. The turbid emulsion was placed in a large-mouthed flask and stirred under medium speed to allow the methylene chloride to evaporate. The resulting white microparticles were allowed to settle, washed with water, and freeze dried. The particles had a particle size of 30-100 μ m.
- 20
- 25

Example 2: Coating Degradable Particles

- 30 1. The particles from Example 1 were emulsified in 30 ml of 1 wt % polyvinylalcohol solution.
2. 10 mg of polystyrene were dissolved in 2 ml of methylene chloride.
- 35 3. The polystyrene solution was added (all at once) to the polyvinylalcohol solution.

- 13 -

4. The resulting emulsion was vortexed for 1 minute and then sonicated for 1 minute, providing a turbid emulsion.
5. The turbid emulsion was placed in a large-mouthed flask and stirred under medium speed to evaporate the methylene chloride. The resulting microparticles were centrifuged, washed, and freeze-dried.
6. The coated particles were viewed using a high-power microscope. The core of degradable material and the polystyrene coating were clearly visible.

Example 3: Degradable Particles Including Chlorhexidene Gluconate

1. 10 mg of chlorhexidene gluconate were added to 5 ml of methylene chloride. The mixture was sonicated to reduce the particle size of the chlorhexidene gluconate. 50 mg of the degradable polymer described in Example 1 were added, and the resulting mixture was vortexed to dissolve the polymer.
2. The methylene chloride solution was added (all at once) to the polyvinylalcohol solution.
3. The resulting emulsion was vortexed for 1 minute and then sonicated for 1 minute, providing a turbid emulsion.
4. The turbid emulsion was placed in a large-mouthed flask and stirred

- 14 -

5 under medium speed to evaporate the methylene chloride. The resulting microparticles were centrifuged, washed, and freeze-dried. The particles then can be coated by the same procedure described in Example 2.

Example 4: Degradable Particles Including Chlorhexidene (Free-Base)

- 10 1. 10 mg of chlorhexidene (free-base) were emulsified in 5 ml of methylene chloride. The emulsion was sonicated to reduce particle size of the chlorhexidene.
- 15 2. 50 mg of the degradable polymer described in Example 1 were added. The mixture was vortexed to dissolve the polymer.
- 20 3. The resulting emulsion was poured into 40 ml of 1% polyvinylalcohol solution, and the resulting mixture vortexed and sonicated, providing a turbid emulsion.
- 25 4. The turbid emulsion was placed in a large-mouthed flask and stirred under medium speed to evaporate the methylene chloride. The resulting microparticles were centrifuged, washed, and freeze-
- 30 dried. The particles then can be coated by the same procedure described in Example 2.

Example 5: Degradable Particles Including Chlorhexidene (Free-Base)

- 35 1. 10 mg of chlorhexidene (free-base) were dissolved in 5 ml of ethyl acetate.
2. 50 mg of the degradabl polymer

- 15 -

described in Example 1 were added. The resulting mixture was vortexed to dissolve the polymer.

5 3. The resulting solution was poured into 40 ml of 1% polyvinylalcohol solution, and the mixture vortexed and sonicated, providing a turbid emulsion.

10 4. The turbid emulsion was placed in a large-mouthed flask and stirred under medium speed to evaporate the ethyl acetate. The resulting microparticles were centrifuged, washed, and freeze-dried. The
15 particles then can be coated by the same procedure described in Example 2.

Other embodiments are within the claims. For example, the entire degradable
20 particle can be composed of the anti-microbial agent and a material like glycerol distearate that is water stable but degrades when exposed to mouth enzymes.

- 16 -

C L A I M S

1. A method for inhibiting bacteria in the mouth of a patient, comprising:
placing a particle comprising a
5 degradable material and an anti-microbial agent in the mouth of a patient, said particle having a water-stable exterior,
said degradable material, after said particle is placed in said mouth, degrading to
10 cause release of said anti-microbial agent, thereby inhibiting bacteria in said mouth of said patient.
2. The method of claim 1, wherein said anti-microbial agent is chlorhexidene or an
15 acceptable salt thereof.
3. The method of claim 1, wherein said degradable material is a degradable polymer.
4. The method of claim 1, wherein said
20 degradable polymer is selected from the group consisting of polyglycolic acid, polylactic acid, copolymers of glycolic acid and lactic acid, and glycerol distearate.
5. The method of claim 1, wherein said
25 water-stable exterior is in the form of a non-porous coating comprising a water stable material which does not significantly degrade when contacted with enzymes found in the mouth.
6. The method of claim 5, wherein said
30 water-stable material is selected from the group consisting of poly(methyl methacrylate), polystyrene, and waxes.
7. The method of claim 1, wherein said
water-stable exterior is in the form of a non-porous coating which degrades when contacted
35 with enzymes found in the mouth.
8. The method of claim 7, wherein said water-stable material comprises glycerol

- 17 -

distearate.

9. The method of claim 1, wherein said degradable material is a material which is water stable.

5 10. The method of claim 9, wherein said degradable material comprises glycerol distearate.

11. The method of claim 1, wherein said anti-microbial agent and said degradable
10 material are dispersed throughout said particle.

12. The method of claim 1, wherein said particle is a microsphere.

13. The method of claim 1, wherein said particle has an average diameter between 0.05 μm
15 and 100 μm , inclusive.

14. The method of claim 13, wherein said particle has an average diameter between 0.1 μm
and 30 μm , inclusive.

15. The method of claim 1, wherein said
20 particle comprises between 1 percent and 75 percent of said anti-microbial agent by weight.

16. A toothbrush comprising a handle and a head with bristles, wherein said bristles
comprise particles comprising a degradable
25 material and an anti-microbial agent, said particle having a water-stable exterior.

17. Dental floss comprising an elongated length of flexible cord comprising particles
comprising a degradable material and an anti-
30 microbial agent, said particle having a water-stable exterior.

18. Toothpaste comprising particles comprising a degradable material and an anti-
microbial agent, said particle having a water-
35 stable exterior.

19. An oral rinse suitable for use in oral care, comprising

- 18 -

water and
particles comprising a degradable
material and an anti-microbial agent, said
particles having a water-stable exterior.

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/US 95/13337

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9311754	24-06-93	CA-A- 2125483	24-06-93
		EP-A- 0616526	28-09-94
		FI-A- 942765	10-06-94
		NO-A- 942170	10-06-94
		US-A- 5286496	15-02-94
		US-A- 5382424	17-01-95
EP-A-0244118	04-11-87	US-A- 4780320	25-10-88
		AU-B- 614061	22-08-91
		AU-B- 7211287	05-11-87
		DE-D- 3787829	25-11-93
		DE-T- 3787829	11-05-94
		JP-A- 63027422	05-02-88
		NO-B- 177125	18-04-95
		US-A- 4919939	24-04-90
WO-A-9220319	26-11-92	FR-A- 2676362	20-11-92
WO-A-9305680	01-04-93	US-A- 5186927	16-02-93
		AU-B- 2573492	27-04-93
		CN-A- 1076078	15-09-93
		DE-T- 4293451	08-09-94
		US-A- 5250288	05-10-93
		US-A- 5300290	05-04-94
		US-A- 5211939	18-05-93
		US-A- 5320842	14-06-94
		ZA-A- 9206907	16-03-93
US-A-4867988	19-09-89	NONE	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/13337

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/16 A61K7/22 A61K9/16 A61K31/155

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO-A-93 11754 (PROCTER & GAMBLE) 24 June 1993 * see claims 1,2; page 2, lines 22-27; page 3, lines 1-20; example 2	1-3,5-7, 9,11-15, 19
Y	* " , page 1, lines 9-17 *	16-18
X	EP-A-0 244 118 (PHARMETRIX CORP) 4 November 1987 * see claims 1,5,7,8; page 5, lines 1-30; page 8, line 16 - page 14, line 2 *	1-7,9, 11-15
Y	* " *	16-18
X	WO-A-92 20319 (OREAL) 26 November 1992 * see claims 1-5, 12, 15 *	1,2,9, 11-15,18
	--- -/-- ---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

23 January 1996

Date of mailing of the international search report

08.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5118 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Isert, B

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No.
PCT/US 95/13337

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO-A-93 05680 (GILLETTE CANADA) 1 April 1993 * see the whole document *	16-18
A	* " "	1-15, 19
A	----- US-A-4 867 988 (CHERNACK MILTON P) 19 September 1989 * see claim 1 * -----	1-19